Get the Stockscreener App
113.99
1.66%
-1.93
After Hours:
113.99
Palvella Therapeutics Inc stock is traded at $113.99, with a volume of 146.37K.
It is down -1.66% in the last 24 hours and down -12.74% over the past month.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
See More
Previous Close:
$115.92
Open:
$116.78
24h Volume:
146.37K
Relative Volume:
0.50
Market Cap:
$1.63B
Revenue:
$1.30M
Net Income/Loss:
$-49.30M
P/E Ratio:
-27.34
EPS:
-4.1688
Net Cash Flow:
$-25.01M
1W Performance:
-0.22%
1M Performance:
-12.74%
6M Performance:
+21.15%
1Y Performance:
+415.56%
1-Day Range:
$113.07
$117.25
1-Week Range:
$101.29
$117.25
52-Week Range:
$20.20
$151.18
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
113.99 | 1.66B | 1.30M | -49.30M | -25.01M | -4.1688 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Mizuho | Outperform |
| Dec-05-25 | Initiated | BTIG Research | Buy |
| Dec-04-25 | Initiated | Craig Hallum | Buy |
| Nov-19-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Kathleen Goin, Palvella COO, sells $475,630 in company stock By Investing.com - Investing.com Australia
Kathleen Goin, Palvella COO, sells $475,630 in company stock - Investing.com
Number of shareholders of Palvella Therapeutics, Inc. – NASDAQ:PVLA - TradingView
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards - Sahm
PVLA Stock Price, Quote & Chart | PALVELLA THERAPEUTICS INC (NASDAQ:PVLA) - ChartMill
Palvella Therapeutics Q1 earnings call highlights - MSN
Palvella presents clinical data on topical rapamycin gel By Investing.com - Investing.com Nigeria
Palvella Reports Positive Phase 3 Data for QTORIN - TipRanks
Palvella presents clinical data on topical rapamycin gel - Investing.com
Palvella's QTORIN™ rapamycin shows strong Phase... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Palvella Therapeutics Reports Positive Phase 3 SELVA and Phase 2 TOIVA Study Results for QTORIN™ Rapamycin in Treating Microcystic Lymphatic Malformations and Cutaneous Venous Malformations - Quiver Quantitative
Rare vascular disease trial: 100% of children improved - Stock Titan
Palvella’s QTORIN Trial Data Reframes Venous Malformation Outlook And Valuation - Yahoo Finance
Palvella Eyes 2027 Launch After Positive Phase 3 Results - MyChesCo
Palvella Therapeutics Reports Positive Phase 2 TOIVA Trial Results for QTORIN Rapamycin in Cutaneous Venous Malformations at SID 2026 - Minichart
Palvella presents Phase 2 data on bleeding reduction treatment - Investing.com UK
Palvella presents Phase 2 data on bleeding reduction treatment By Investing.com - Investing.com South Africa
Palvella Unveils Promising Phase 2 Data for QTORIN - TipRanks
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology - The Manila Times
Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations - TradingView
Palvella presents positive Phase 2 TOIVA data showing significant bleeding reduction with QTORIN rapamycin - TradingView
New skin trial eases bleeding in rare disease affecting over 75,000 in U.S. - Stock Titan
Palvella targets 2H 2026 NDA filing while outlining >$1B peak US sales potential for QTORIN rapamycin in microcystic lymphatic malformations - MSN
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market - Sahm
Palvella Therapeutics approved for transfer to Nasdaq Global Market - MSN
Palvella Therapeutics moves to Nasdaq Global Market By Investing.com - Investing.com India
Palvella Therapeutics Upgrades Listing to Nasdaq Global Market - Moomoo
Palvella Therapeutics, Inc. Files Form 8-K with SEC – Company Details, Address, and Stock Information (NASDAQ: PVLA) 161851 - Minichart
Palvella Therapeutics announces uplisting to the Nasdaq Global Market - marketscreener.com
Palvella Therapeutics to transfer listing to Nasdaq Global Market By Investing.com - Investing.com India
Palvella Therapeutics to transfer listing to Nasdaq Global Market - Investing.com
Palvella Therapeutics moves to Nasdaq Global Market - Investing.com
Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market - TradingView
Palvella Therapeutics, Inc. Primary Exchange Listing will Change to Nasdaq Global Market from Nasdaq Capital Market - marketscreener.com
Palvella Therapeutics | 8-K: Current report - Moomoo
Stifel Maintains Palvella Therapeutics (PVLA) Buy Recommendation - MSN
Stephens initiates Palvella stock with overweight rating, $220 target By Investing.com - Investing.com Canada
Stephens & Co. initiates coverage of Palvella Therapeutics (PVLA) with overweight recommendation - MSN
Palvella Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
Mizuho Trims Price Target on Palvella Therapeutics to $240 From $250, Keeps Outperform Rating - Moomoo
Palvella Therapeutics Doses First Patients in Phase 2 Trial for Rare Skin Disease - Moomoo
Palvella Therapeutics: Q1 Earnings Snapshot - theheraldreview.com
Palvella Therapeutics Inc Stock (PVLA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):